61.64 -0.46 (-0.74%)
Pre-Market: 6:36AM EST
Previous Close | 62.59 |
Open | 62.43 |
Bid | 61.56 x 1100 |
Ask | 62.49 x 1000 |
Day's Range | 61.82 - 63.16 |
52 Week Range | 45.76 - 67.16 |
Volume | 14,258,545 |
Avg. Volume | 11,724,745 |
Market Cap | 139.134B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.99 |
Earnings Date | May 05, 2021 - May 10, 2021 |
Forward Dividend & Yield | 1.96 (3.16%) |
Ex-Dividend Date | Dec 31, 2020 |
1y Target Est | 75.13 |
BMS Receives Positive CHMP Opinion for Opdivo® in Combination with Cabometyx® as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Bristol Myers Squibb (NYSE: BMY) is generating plenty of cash flow and recently used $4 billion of its nest egg to pay down debt. In this video from Motley Fool Live recorded on Feb. 8 (before the transaction was completed), Fool.com contributors Brian Orelli and Keith Speights discuss why that might not be the best use of the pharma company's cash. Brian Orelli: The company plans to retire $4 billion in debt.
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important companies in the world, even if they have been much maligned as […]